p53 mutants: The Achilles' heel of human cancers?

Cell Cycle

Volumn 3, Issue 8, 2004, Pages 1028-1032

  Brachmann, Rainer K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Cancer; Drug target; High throughput screen; Missense mutation; p53; Structure based drug design; Suppressor mutation; Tumor suppressor

Indexed keywords

MUTANT PROTEIN; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; DRUG TARGETING; GENE INACTIVATION; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; MISSENSE MUTATION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 13944260092     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.8.1076     Document Type: Review

References (72)

1. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003; 21:292-300.
2. Campling BG, El-Deiry WS. Clinical implication of p53 mutation in lung cancer. Mol Biotechnol 2003; 24:141-56.
3. Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat 2003; 21:271-6.
4. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with nonsmall cell lung cancer: A meta-analysis. Clin Cancer Res 2000; 6:4055-63.
5. Peller S, Rotter V. TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance. Hum Mutat 2003; 21:277-84.
6. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001; 1:233-40.
7. Wallace-Brodeur RR, Lowe SW. Clinical implications of p53 mutations. Cell Mol Life Sci 1999; 55:64-75.
8. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001; 268:2764-72.
9. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: The molecular basis for p53 regulation. Curr Opin Cell Biol 2003; 15:164-71.
10. Xu Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ 2003; 10:400-3.
11. Wahl GM, Carr AM. The evolution of diverse biological responses to DNA damage: Insights from yeast and p53. Nat Cell Biol 2001; 3:E277-86.
12. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10.
13. Vousden KH, Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002; 2:594-604.
14. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31.
15. Oren M. Decision making by p53: Life, death and cancer. Cell Death Differ 2003; 10:431-42.
16. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187:112-26.
17. Chipuk JE, Green DR. Cytoplasmic p53: Bax and Forward. Cell Cycle 2004; 3:429-31.
18. Lane DP. p53, guardian of the genome. Nature 1992; 358:15-6.
19. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base No 5. Lyon: IARC Press, 2001.
20. Harris CC. p53 tumor suppressor gene: From the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 1996; 17:1187-98.
21. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat 2002; 19:607-14.
22. Beroud C, Soussi T. The UMD-p53 database: New mutations and analysis tools. Hum Mutat 2003; 21:176-81.
23. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 1994; 265:346-55.
24. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001; 1:68-76.
25. Blagosklonny MV. p53 from complexity to simplicity: Mutant p53 stabilization, gain-of-function, and dominant-negative effect. Faseb J 2000; 14:1901-7.
26. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res 2000; 60:6788-93.
27. Roemer K. Mutant p53: Gain-of-function oncoproteins and wild-type p53 inactivators. Biol Chem 1999; 380:879-87.
28. van Oijen MG, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 2000; 6:2138-45.
29. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74:957-67.
30. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-10.
31. Bykov VJ, Selivanova G, Wiman KG. Small molecules that reactivate mutant p53. Eur J Cancer 2003; 39:1828-34.
32. Wang W, Rastinejad F, El-Deiry WS. Restoring p53-dependent tumor suppression. Cancer Biol Ther 2003; 2:S55-63.
33. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999; 286:2507-10.
34. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8:282-8.
35. Sugikawa E, Hosoi T, Yazaki N, Gamanuma M, Nakanishi N, Ohashi M. Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res 1999; 19:3099-108.
36. Peng Y, Li C, Chen L, Sebti S, Chen J. Rescue of mutant p53 transcription function by ellipticine. Oncogene 2003; 22:4478-87.
37. Maurici D, Monti P, Campomenosi P, North S, Frebourg T, Fronza G, Hainaut P. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene 2001; 20:3533-40.
38. Wang W, Takimoto R, Rastinejad F, El-Deiry WS. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003; 23:2171-81.
39. Luu Y, Li G. The p53-stabilizing compound CP-31398 enhances ultraviolet-B-induced apoptosis in a human melanoma cell line MMRU. J Invest Dermatol 2002; 119:1207-9.
40. Luu Y, Li G. The p53-stabilizing compound, CP-31398, does not enhance chemosensitivity in human melanoma cells. Anticancer Res 2003; 23:99-105.
41. Herbert BS, Pearce VP, Hynan LS, LaRue DM, Wright WE, Kopelovich L, Shay JW. A peroxisome proliferator-activated receptor-gamma agonist and the p53 rescue drug CP-31398 inhibit the spontaneous immortalization of breast epithelial cells. Cancer Res 2003; 63:1914-9.
42. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 2003; 22:8233-45.
43. Stanhope-Baker P, Kessler PM, Li W, Agarwal ML, Williams BR. The WT1 target gene Podocalyxin is transcriptionally repressed by p53. J Biol Chem 2004.
44. Luu Y, Bush J, Cheung Jr KJ, Li G. The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. Exp Cell Res 2002; 276:214-22.
45. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, el-Deiry WS. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 2002; 1:47-55.
46. Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 2002; 21:2119-29.
47. Bykov VJ, Issaeva N, Selivanova G, Wiman KG. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: A statistical analysis of information in the National Cancer Institute database. Carcinogenesis 2002; 23:2011-8.
48. Chipuk JE, Maurer U, Green DR, Schuler M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 2003; 4:371-81.
49. Shen H, Chen ZJ, Zilfou JT, Hopper E, Murphy M, Tew KD. Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. J Pharmacol Exp Ther 2001; 297:1067-73.
50. Acosta JC, Richard C, Delgado MD, Horita M, Rizzo MG, Fernandez-Luna JL, Leon J. Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Mol Cancer Ther 2003; 2:893-900.
51. Lee EJ, Gerhold M, Palmer MW, Christen RD. p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection. Br J Cancer 2003; 88:754-9.
52. North S, El-Ghissassi F, Pluquet O, Verhaegh G, Hainaut P. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 2000; 19:1206-14.
53. North S, Pluquet O, Maurici D, El-Ghissassi F, Hainaut P. Restoration of wild-type conformation and activity of a temperaturesensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol Carcinog 2002; 33:181-8.
54. Pluquet O, North S, Richard MJ, Hainaut P. Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity. Biochem Pharmacol 2003; 65:1129-37.
55. Pluquet O, North S, Bhoumik A, Dimas K, Ronai Z, Hainaut P. The cytoprotective aminothiol WR1065 activates p53 through a nongenotoxic signaling pathway involving c-Jun N-terminal kinase. J Biol Chem 2003; 278:11879-87.
56. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T, Lu X. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8:781-94.
57. Gorina S, Pavletich NP. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 1996; 274:1001-5.
58. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, Proctor MR, Rudiger S, Fersht AR. A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 2002; 99:937-42.
59. Friedler A, DeDecker BS, Freund SM, Blair C, Rudiger S, Fersht AR. Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: Implications for "mutant conformation." J Mol Biol 2004; 336:187-96.
60. Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, Selivanova G. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci USA 2003; 100:13303-7.
61. Abarzua P, LoSardo JE, Gubler ML, Spathis R, Lu YA, Felix A, Neri A. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene 1996; 13:2477-82.
62. Kim AL, Raffo AJ, Brandt-Rauf PW, Pincus MR, Monaco R, Abarzua P, Fine RL. Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J Biol Chem 1999; 274:34924-31.
63. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Grafstrom RC, Wiman KG. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 1997; 3:632-8.
64. Selivanova G, Ryabchenko L, Jansson E, Iotsova V, Wiman KG. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol 1999; 19:3395-402.
65. Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2004; 2:E36.
66. Lane D. Curing cancer with p53. N Engl J Med 2004; 350:2711-2.
67. Ahn J, Prives C. The C-terminus of p53: The more you learn the less you know. Nat Struct Biol 2001; 8:730-2.
68. Brachmann RK, Yu K, Eby Y, Pavletich NP, Boeke JD. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J 1998; 17:1847-59.
69. Wieczorek AM, Waterman JL, Waterman MJ, Halazonetis TD. Structure-based rescue of common tumor-derived p53 mutants. Nat Med 1996; 2:1143-6.
70. Baroni TE, Wang T, Qian H, Dearth LR, Truong LN, Zeng J, Denes AE, Chen SW, Brachmann RK. A global suppressor motif for p53 cancer mutants. Proc Natl Acad Sci USA 2004; 101:4930-5.
71. Inga A, Resnick MA. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants. Oncogene 2001; 20:3409-19.
72. Anderson AC. The process of structure-based drug design. Chem Biol 2003; 10:787-97.